Irsogladine is aPDE4 inhibitorandmuscarinic acetylcholine receptorbinder. Target:PDE4;mACHRIrsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P< 0.02, P< 0.001), in tPA-deficient mice by 42.6 and 46% (P< 0.001, P< 0.001), and in uPA-deficient mice by 27.2 and 46% (P< 0.05, p< 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of thePKApathway. It also suggests a useful adjuvant of Irsogladine to pancreaticcancertherapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].

372.16

C₁₃H₁₁Cl₂N₅O₄

84504-69-8

马来酸伊索拉定

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.